Abstract
BackgroundDue to tumor heterogeneity, the diagnosis, treatment, and prognosis of patients with lung squamous cell carcinoma (LUSC) are difficult. DNA methylation is an important regulator of gene expression, which may help the diagnosis and therapy of patients with LUSC.MethodsIn this study, we collected the clinical information of LUSC patients in the Cancer Genome Atlas (TCGA) database and the relevant methylated sequences of the University of California Santa Cruz (UCSC) database to construct methylated subtypes and performed prognostic analysis.ResultsNine hundred sixty-five potential independent prognosis methylation sites were finally identified and the genes were identified. Based on consensus clustering analysis, seven subtypes were identified by using 965 CpG sites and corresponding survival curves were plotted. The prognostic analysis model was constructed according to the methylation sites’ information of the subtype with the best prognosis. Internal and external verifications were used to evaluate the prediction model.ConclusionsModels based on differences in DNA methylation levels may help to classify the molecular subtypes of LUSC patients, and provide more individualized treatment recommendations and prognostic assessments for different clinical subtypes. GNAS, FZD2, FZD10 are the core three genes that may be related to the prognosis of LUSC patients.
Highlights
Due to tumor heterogeneity, the diagnosis, treatment, and prognosis of patients with lung squamous cell carcinoma (LUSC) are difficult
Select potential methylation sites associated with the prognosis of patients After preprocess the downloaded patients data according to the description in Materials and Methods, we identified 21,122 methylation sites
With p < 0.05 as the screening condition, the univariate Cox regression analysis was used to select the CpG sites, which could be used to serve as potential DNA methylation biomarkers for overall survival of patients with LUSC
Summary
The diagnosis, treatment, and prognosis of patients with lung squamous cell carcinoma (LUSC) are difficult. DNA methylation is an important regulator of gene expression, which may help the diagnosis and therapy of patients with LUSC. 66% patients have lost the opportunity to undergo radical surgery after the diagnosis of lung cancer in China [2]. Non-small cell lung cancer (NSCLC), a heterogeneous disease, accounts for more than four-fifths of all lung cancers, and the pathological classification and clinical stage of patients are closely related to their prognosis [3]. In the past two decades, the epigenetic understanding of lung cancer has developed exponentially [5]. Epigenetic research has provided key data for the occurrence of lung cancer.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
